0.23
-0.0337(-12.81%)
Currency In USD
| Previous Close | 0.26 |
| Open | 0.24 |
| Day High | 0.24 |
| Day Low | 0.22 |
| 52-Week High | 3 |
| 52-Week Low | 0.22 |
| Volume | 57.68M |
| Average Volume | 2.09M |
| Market Cap | 2.39M |
| PE | -0.26 |
| EPS | -0.87 |
| Moving Average 50 Days | 0.61 |
| Moving Average 200 Days | 0.86 |
| Change | -0.03 |
If you invested $1000 in Adial Pharmaceuticals, Inc. (ADIL) since IPO date, it would be worth $2.26 as of June 25, 2025 at a share price of $0.229. Whereas If you bought $1000 worth of Adial Pharmaceuticals, Inc. (ADIL) shares 5 years ago, it would be worth $6.2 as of June 25, 2025 at a share price of $0.229.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering
GlobeNewswire Inc.
Jun 17, 2025 12:00 PM GMT
GLEN ALLEN, Va., June 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and r
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting
GlobeNewswire Inc.
Jun 16, 2025 12:00 PM GMT
End of Phase 2 Meeting has been Rescheduled for July 29th Meeting to Discuss Upcoming Clinical Development Plan and Protocol Designs Strategic Partnership Discussions Expected to Accelerate Following a Positive FDA Meeting GLEN ALLEN, Va., June 16,
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
GlobeNewswire Inc.
Jun 11, 2025 12:00 PM GMT
Engages with Cytel’s Machine Learning Technology on Data Analysis and Phase 3 Trial DesignGLEN ALLEN, Va., June 11, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical c